Advertisement

Canadian Journal of Anesthesia

, Volume 54, Issue 9, pp 689–695 | Cite as

Sugammadex: an opportunity for more thinking or more cookbook medicine?

  • François Donati
Editorial

Le sugammadex: une occasion de réfléchir ou de suivre la recette?

References

  1. 1.
    Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007; 104:575–81.PubMedCrossRefGoogle Scholar
  2. 2.
    Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002; 41:266–70.PubMedCrossRefGoogle Scholar
  3. 3.
    Kopman AF. Sugammadex: a revolutionary approach to neuromuscular antagonism. Anesthesiology 2006; 104:631–3.PubMedCrossRefGoogle Scholar
  4. 4.
    Miller RD. Sugammadex: an opportunity to change the practice of anesthesiology?Anesth Analg 2007; 104:477–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Kim KS, Cheong MA, Lee HJ, Lee JM. Tactile assessment for the reversibility of rocuronium-induced neuromuscular blockade during propofol or sevoflurane anesthesia. Anesth Analg 2004; 99:1080–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis. Br J Anaesth 2007; 98:302–16.PubMedCrossRefGoogle Scholar
  7. 7.
    Plaud B, Proost JH, Wierda JM, Barre J, Debaene B, Meistelman Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans. Clin Pharmacol Ther 1995; 58:185–91.PubMedCrossRefGoogle Scholar
  8. 8.
    Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003; 99:632–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Gijsenbergh F, Ramael S, Houwing N, van IerselT. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103:695–703.PubMedCrossRefGoogle Scholar
  10. 10.
    Sorgenfrei IF, Norrild Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dosefinding and safety study. Anesthesiology 2006; 104:667–74.PubMedCrossRefGoogle Scholar
  11. 11.
    Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 2007; 106:935–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Eleveld DJ, Kuizenga K, Proost JH, Wierda JM. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg 2007; 104:582–4.PubMedCrossRefGoogle Scholar

Copyright information

© Canadian Anesthesiologists 2007

Authors and Affiliations

  • François Donati
    • 1
  1. 1.Department of AnesthesiologyHôpital Maisonneuve-Rosemont and Université de MontréalMontréalCanada

Personalised recommendations